Cannabidiol and Cannabigerol Modulate Cariogenic Virulence in Cross-Kingdom Biofilms In Vitro

Cannabidiol-loaded nanostructured lipid carriers (NLCs) for dermal delivery: enhancement of photostability, cell viability, and anti-inflammatory activity

10.3390/pharmaceutics15020537 · doi-reference

Lipid nanoparticle formulations for the skin delivery of cannabidiol

10.3390/pharmaceutics16121490 · doi-reference

Enhancement of cannabidiol oral bioavailability through the development of nanostructured lipid carriers: in vitro and in vivo evaluation studies

10.1007/s13346-024-01766-9 · doi-reference

Phytocannabinoids regulate inflammation in IL-1β-stimulated human gingival fibroblasts

10.1111/jre.13050 · doi-reference

Antibiofilm and immune-modulatory activity of cannabidiol and cannabigerol in oral environments—in vitro study

10.3390/antibiotics13040342 · doi-reference

Acute and chronic cannabidiol treatment: in vitro toxicological aspects on human oral cells

10.1016/j.fct.2024.114513 · doi-reference

Proliferative effect of cannabidiol in human gingival fibroblasts via the mitogen-activated extracellular signal-regulated kinase (MEK) 1/2

10.1111/jre.13178 · doi-reference

Effect of cannabidiol on human gingival fibroblast extracellular matrix metabolism: MMP production and activity, and production of fibronectin and transforming growth factor β

10.1111/j.1600-0765.2011.01435.x · doi-reference

Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease

10.1073/pnas.0813394106 · doi-reference

Hsp90 governs dispersion and drug resistance of fungal biofilms

10.1371/journal.ppat.1002257 · doi-reference

Proteomic and metabolomic analyses reveal the antibacterial mechanism of cannabidiol against gram-positive bacteria

10.1016/j.jprot.2025.105411 · doi-reference

Proteomic changes in methicillin-resistant Staphylococcus aureus exposed to cannabinoids

10.1021/acs.jnatprod.3c00064 · doi-reference

Analogue regulated Streptococcus mutans and Streptococcus sanguinis dual-species biofilms

10.1016/j.identj.2024.11.010 · doi-reference

Quorum sensing regulation of competence and bacteriocins in Streptococcus pneumoniae and mutans

10.3390/genes8010015 · doi-reference

Intracellular signaling by the comRS System in Streptococcus mutans genetic competence

10.1128/msphere.00444-18 · doi-reference

Uncovering the hidden antibiotic potential of cannabis

10.1021/acsinfecdis.9b00419 · doi-reference

Benefits, toxicity and current market of cannabidiol in edibles

10.1080/10408398.2021.2024493 · doi-reference

The antimicrobial potential of cannabidiol

10.1038/s42003-020-01530-y · doi-reference

Treatment of stage I-III periodontitis—the EFP S3 level clinical practice guideline

10.1111/jcpe.13290 · doi-reference

Targeting microbial biofilms: current and prospective therapeutic strategies

10.1038/nrmicro.2017.99 · doi-reference

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

10.1186/s13059-014-0550-8 · doi-reference

Fast gapped-read alignment with Bowtie 2

10.1038/nmeth.1923 · doi-reference

HISAT: a fast spliced aligner with low memory requirements

10.1038/nmeth.3317 · doi-reference

Quantification of biofilm structures by the novel computer program COMSTAT

10.1099/00221287-146-10-2395 · doi-reference

Oral candida predicts Streptococcus mutans emergence in underserved US infants

10.1177/00220345211012385 · doi-reference

Natural antimicrobials ε-poly-L-lysine and nisin A for control of oral microflora

10.1007/s12602-009-9020-0 · doi-reference

Effect of probiotic lactobacillus plantarum on Streptococcus mutans and Candida albicans clinical isolates from children with early childhood caries

10.3390/ijms24032991 · doi-reference

Mutacins from Streptococcus mutans UA159 are active against multiple streptococcal species

10.1128/aem.02320-10 · doi-reference

Potential combinatory effect of cannabidiol and triclosan incorporated into sustained release delivery system against oral candidiasis

10.3390/pharmaceutics14081624 · doi-reference

Anti-biofilm activity of cannabidiol against Candida albicans

10.3390/microorganisms9020441 · doi-reference

Anti-bacterial properties of cannabigerol toward Streptococcus mutans

10.3389/fmicb.2021.656471 · doi-reference

The antibacterial effect of cannabigerol toward Streptococcus mutans is influenced by the autoinducers 21-CSP and AI-2

10.3390/biomedicines11030668 · doi-reference

Anti-biofilm activity of cannabigerol against Streptococcus mutans

10.3390/microorganisms9102031 · doi-reference

Anti-bacterial effect of cannabidiol against the cariogenic Streptococcus mutans bacterium: an in vitro study

10.3390/ijms232415878 · doi-reference

Antimicrobial potential of cannabinoids: a scoping review of the past 5 years

10.3390/microorganisms13020325 · doi-reference

Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis

10.1016/j.phymed.2025.157066 · doi-reference

Cannabidiol and neurodegeneration: from molecular mechanisms to clinical benefits

10.1016/j.arr.2024.102386 · doi-reference

Cannabidiol: state of the art and new challenges for therapeutic applications

10.1016/j.pharmthera.2017.02.041 · doi-reference

Interkingdom assemblages in human saliva display group-level surface mobility and disease-promoting emergent functions

10.1073/pnas.2209699119 · doi-reference

Candida albicans mannans mediate Streptococcus mutans exoenzyme GtfB binding to modulate cross-kingdom biofilm development in vivo

10.1371/journal.ppat.1006407 · doi-reference